According to the 2025 hypertension guidelines, should the work‑up for resistant hypertension include screening for primary aldosteronism even when potassium levels are normal, and is renal denervation now considered an adjunctive option for selected patients?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 13, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Screening for Primary Aldosteronism in Resistant Hypertension

Yes, the 2025 AHA/ACC hypertension guidelines explicitly recommend screening for primary aldosteronism in ALL patients with resistant hypertension regardless of potassium levels, and have expanded screening consideration to stage 2 hypertension. 1

Primary Aldosteronism Screening: The First Part is TRUE

Mandatory Screening in Resistant Hypertension

Screen all resistant hypertension patients for primary aldosteronism even with normal potassium 1. This is critical because:

  • Hypokalemia is absent in the majority of primary aldosteronism cases 1
  • Normokalemia has low negative predictive value for excluding the diagnosis 1
  • Primary aldosteronism occurs in approximately 20% of resistant hypertension patients 1
  • The prevalence can reach 20-35% in resistant hypertension populations 1

Expanded Screening to Stage 2 Hypertension

The 2025 guidelines now state that screening for primary aldosteronism may be considered in adults with stage 2 hypertension to increase detection rates 1. This represents a significant expansion from prior recommendations that focused primarily on resistant hypertension.

Why This Matters for Morbidity and Mortality

Primary aldosteronism carries substantially worse outcomes than primary hypertension even when blood pressure levels are matched 1:

  • 2.0-fold increased risk of heart failure
  • 2.8-fold increased risk of stroke
  • 1.7-fold increased risk of coronary artery disease
  • 4.0-fold increased risk of atrial fibrillation
  • Increased kidney damage 1

Targeted treatment with adrenalectomy or mineralocorticoid receptor antagonists (spironolactone/eplerenone) improves kidney and cardiovascular outcomes 1, making early detection essential.

How to Screen Properly

The Aldosterone-to-Renin Ratio (ARR)

Use the plasma aldosterone concentration, renin activity, and aldosterone-to-renin ratio as the screening test 1:

  • ARR cutoff: typically 30 (when aldosterone in ng/dL and renin activity in ng/mL/h) 1
  • Alternative thresholds of 20 or 40 are also supported 1
  • Plasma aldosterone should be ≥10 ng/dL for positive interpretation 1
  • Renin activity typically suppressed (<1 ng/mL/h) in primary aldosteronism 1

Critical Testing Conditions

  • Unrestricted salt intake before testing 1
  • Serum potassium in normal range (to avoid false-negatives) 1
  • Ideally withdraw mineralocorticoid receptor antagonists 4 weeks before testing 1

Common Pitfall: Medication Management

You do NOT need to withdraw all antihypertensive medications 1. The guidelines explicitly address this barrier to screening:

  • Beta blockers and central-alpha agonists: suppress both renin and aldosterone 1
  • ACE inhibitors and ARBs: stimulate renin, suppress aldosterone 1
  • Thiazide-type and loop diuretics: stimulate both renin and aldosterone 1

Growing evidence supports screening despite treatment with these medications 1, as the older guidance to withdraw all medications has been disputed and created a major barrier to screening.

Renal Denervation: The Second Part Requires Clarification

The provided 2025 guideline evidence does NOT mention renal denervation as an adjunct option for resistant hypertension. The guideline excerpts focus extensively on primary aldosteronism screening but contain no discussion of renal denervation procedures.

While renal denervation has been studied in resistant hypertension trials, I cannot confirm from the provided 2025 AHA/ACC guideline evidence that it is now recommended as an adjunctive option. This portion of the statement cannot be verified as accurate based on the guideline documents provided.

The Underdiagnosis Crisis

Despite clear recommendations, only 1-2% of eligible patients are actually screened 1, 2. This represents a massive gap between guideline recommendations and clinical practice, resulting in preventable cardiovascular and renal complications.

Bottom line: Screen ALL resistant hypertension patients for primary aldosteronism regardless of potassium levels, and consider screening in stage 2 hypertension. The renal denervation claim cannot be confirmed from the 2025 guidelines provided.

References

Related Questions

What is the recommended approach to diagnose and manage primary hyperaldosteronism in a patient with resistant hypertension and hypokalemia?
If primary hyperaldosteronism is suspected in this patient, how should the management be altered?
In a 25-year-old man with resistant hypertension, hypokalemia, metabolic alkalosis, and a family history of stroke, which investigation is appropriate to evaluate the cause of his uncontrolled blood pressure?
What is the appropriate evaluation and management for a 54-year-old male with primary hyperaldosteronism presenting with heat‑induced palpitations and generalized weakness?
In a 33-year-old pregnant woman with hypertension and elevated blood pressure, should aldosterone be measured now?
What did the Global Initiative for Asthma (GINA) trial demonstrate about using an inhaled corticosteroid–formoterol combination as an as‑needed reliever compared with a short‑acting β2‑agonist alone?
How should a 40 mm echogenic hepatic nodule be evaluated and managed?
Does Zenhale (budesonide/formoterol) have the same level of evidence as Symbicort (budesonide/formoterol) for use in SMART (Single Maintenance And Reliever Therapy) or MART (Maintenance And Reliever Therapy) regimens?
Should subspecialist pediatricians also be involved in the same responsibilities as general pediatricians, including health supervision, screening, and care coordination?
What is the recommended treatment for sub‑acute lateral epicondylitis (tennis elbow)?
What is the recommended workup and initial management for a patient presenting with right‑ear unilateral tinnitus, head tremor, and vertigo?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.